Asthma Drug Under Scrutiny
The Food and Drug Administration issued a Safety Announcement warning that the asthma drug Xolair® increases the risk of heart attack, stroke, chest pain, and blood clots, among other serious problems.
Xolair® is an injectable drug that was approved in 2003 to treat moderate to severe asthma in adults and children 12 and over whose condition could not be controlled by inhaled steroids alone. Xolair is also approved in the treatment of chronic idiopathic urticaria, a form of chronic hives, in adults and adolescents.
The attorneys at Harman Law LLC will continue to investigate Xolair® and the recent FDA warning about the drug. If you or someone you know has experienced harm from Xolair®, contact Harman Law LLC at (404) 554-0777 or fill out the “contact us” form on this page. You will receive a no cost, no obligation consultation to learn your rights and may be eligible for compensation, though there may be a time limit to file a claim.
If you are currently experiencing any health-related issues from Xolair®, consult your medical professional immediately.
The FDA added information about the increased risk to the drug’s label after analyzing findings from a five-year safety study submitted by the drug’s manufacturer, Genentech, a unit of Roche Holding AG, and 25 clinical trials comparing Xolair® to a placebo. The FDA said that the data suggested a “serious safety signal.” The FDA, however, was unable to determine the full extent of the safety concerns for Xolair® due to “weaknesses” in how the manufacturer “designed and carried out” the five-year study.
Harman Law LLC represents clients across the country who have been injured by dangerous and defective drugs and medical devices.
Posted on behalf of